Johnson & Johnson (JNJ)
148.53
-1.03
(-0.69%)
USD |
NYSE |
Apr 24, 16:00
148.21
-0.32
(-0.22%)
Pre-Market: 04:10
Johnson & Johnson Cash from Financing (TTM): -15.82B for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -15.82B |
| September 30, 2023 | -9.47B |
| June 30, 2023 | -2.078B |
| March 31, 2023 | 1.652B |
| December 31, 2022 | -8.871B |
| September 30, 2022 | -14.01B |
| June 30, 2022 | -12.29B |
| March 31, 2022 | -13.31B |
| December 31, 2021 | -14.05B |
| September 30, 2021 | -16.26B |
| June 30, 2021 | -9.852B |
| March 31, 2021 | -6.93B |
| December 31, 2020 | -6.12B |
| September 30, 2020 | -4.548B |
| June 30, 2020 | -12.64B |
| March 31, 2020 | -16.81B |
| December 31, 2019 | -18.02B |
| September 30, 2019 | -20.33B |
| June 30, 2019 | -19.92B |
| March 31, 2019 | -18.06B |
| December 31, 2018 | -18.51B |
| September 30, 2018 | -15.66B |
| June 30, 2018 | -14.25B |
| March 31, 2018 | -13.49B |
| December 31, 2017 | -7.673B |
| Date | Value |
|---|---|
| September 30, 2017 | -7.60B |
| June 30, 2017 | -8.976B |
| March 31, 2017 | -8.097B |
| December 31, 2016 | -8.551B |
| September 30, 2016 | -8.381B |
| June 30, 2016 | -6.776B |
| March 31, 2016 | -8.513B |
| December 31, 2015 | -11.14B |
| September 30, 2015 | -8.70B |
| June 30, 2015 | -12.58B |
| March 31, 2015 | -12.67B |
| December 31, 2014 | -12.50B |
| September 30, 2014 | -10.46B |
| June 30, 2014 | -9.262B |
| March 31, 2014 | -8.371B |
| December 31, 2013 | -6.091B |
| September 30, 2013 | -8.744B |
| June 30, 2013 | -5.878B |
| March 31, 2013 | -20.16B |
| December 31, 2012 | -20.56B |
| September 30, 2012 | -19.85B |
| June 30, 2012 | -20.43B |
| March 31, 2012 | -4.81B |
| December 31, 2011 | -4.452B |
| September 30, 2011 | -1.09B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-20.33B
Minimum
Sep 2019
1.652B
Maximum
Mar 2023
-11.56B
Average
-12.64B
Median
Jun 2020
Cash from Financing (TTM) Benchmarks
| Amgen Inc | 21.05B |
| Gilead Sciences Inc | -5.125B |
| Eli Lilly and Co | 3.496B |
| Merck & Co Inc | -4.81B |
| Shockwave Medical Inc | 600.40M |